Search results for "Drug Safety"
Latest diabetes drugs have a learning curve
The onus is on internists to understand the newer classes of incretins such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors. They hold promise for better treatments, but they are new and not as well understood as older treatments.
https://immattersacp.org/archives/2015/10/diabetes.htm
1 Oct 2015
New warning for testosterone, approval for inhaled insulin
This update covers a revised warning on testosterone products about the risk of venous thromboembolism, and approval of a fast-acting inhaled insulin to treat diabetes in adults.
https://immattersacp.org/archives/2014/09/fda.htm
1 Sep 2014
New grass allergy treatment, opioid overdose solution
This update covers approval of an allergen extract to treat allergic rhinitis induced by grass pollen and of a handheld injector of naloxone for emergency treatment of known or suspected opioid overdose.
https://immattersacp.org/archives/2014/06/fda.htm
1 Jun 2014
FDA asks clinicians to limit prescriptions of acetaminophen
The FDA recommends that clinicians stop prescribing and dispensing combination drugs that contain more than 325 mg of acetaminophen per dose.
https://immattersacp.org/archives/2014/05/acetaminophen.htm
1 May 2014
Anxiolytic, hypnotic drugs may be associated with increased long-term mortality
Anxiolytic and hypnotic drugs may be associated with increased long-term mortality, according to a new study.
https://immattersacp.org/weekly/archives/2014/04/01/6.htm
1 Apr 2014
Recommended: Move hydrocodone combo products to schedule II
This regulatory update covers a proposed reclassification of hydrocodone combination products from schedule III to schedule II, and approval of an extended-release version of hydrocodone bitartrate for pain management.
https://immattersacp.org/archives/2014/01/fda.htm
1 Jan 2014
New COPD treatment, warnings on insomnia and migraine drugs
This regulatory update covers approval of a combined long-term maintenance treatment for chronic obstructive pulmonary disease, warnings against driving after taking insomnia drugs and on use of migraine drugs in pregnant women, and more.
https://immattersacp.org/archives/2013/07/fda.htm
1 Jul 2013
Expanded approval on rivaroxaban, reassurance on dabigatran
This regulatory update covers an expanded indication for rivaroxaban and an announcement that bleeding rates do not appear to be higher with dabigatran than with warfarin.
https://immattersacp.org/archives/2013/01/fda.htm
1 Jan 2013
Ondansetron 32-mg dose pulled from market
The 32-mg, single intravenous dose of ondansetron hydrochloride (Zofran) has been pulled from the market due to its cardiac risks, the FDA recently announced.
https://immattersacp.org/weekly/archives/2012/12/11/9.htm
11 Dec 2012
Warning on PPIs and C. diff, contraceptive pill mixup
Recalls, warnings, approvals and other regulatory news.
https://immattersacp.org/archives/2012/04/fda.htm
1 Apr 2012